Latest Presentation
Presentation of Telomir-1 at the National Press Club in Washington, DC, on April 15, 2024
Latest News
Telomir Pharmaceuticals’ Anti-Aging Expert and NYT Bestselling Author Michael F. Roizen, MD, to Present Promising Pre-Clinical Data for Age-Reversal Drug Telomir-1 at the National Press Club in Washington, DC, on April 15, 2024
View Press ReleaseUPDATE – Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines
View Press ReleaseTelomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines
View Press Release
Email Alerts
Sign up today and receive company updates straight to your inbox.
Company Overview
At Telomir Pharmaceuticals, we are committed to developing breakthrough science to address the root causes of difficult to treat diseases. By partnering with the brightest minds in science and healthcare, we have the potential to discover and develop ground-breaking treatments to bring about better health for patients and change the future of medicine.
IR Contacts
Headquarters
Telomir Pharmaceuticals, Inc.
855 Wolfe St.
Ste 601.1
Baltimore, MD 21205
United States
T: 813-864-2558
telomir@kcsa.com
Investor Relations
KCSA
Phil Carlson
261 Madison Avenue, 9th Fl.
New York, NY 10016
T: 212-896-1233
telomir@kcsa.com
Transfer Agent
Equiniti
6201 15th Avenue
Brooklyn, NY 11219
T: US 800-401-1957
T: Canada/US Virgin Islands 800-468-9716
T: Other International Access Codes
susan.silber@equiniti.com